In part 1 of this Exclusive Interview, Tony Galliani shares an overview of a new smart insulin delivery device in a conversation with Diabetes in Control Publisher Steve Freed.

In part 2 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about their target market, patients who are not using insulin pumps.

In part 3 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about the features of the new smart pen and how it compares to pumps.

In part 4 of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about how the smart pen works for basal-bolus injections.

In part 5 of this Exclusive Interview, Tony Galliani explains the warranty, maintenance, and insurance coverage of the new smart pen in a conversation with Diabetes in Control Publisher Steve Freed.

In part 6, the conclusion of this Exclusive Interview, Tony Galliani talks with Diabetes in Control Publisher Steve Freed about the connectivity of the InPen with other devices.

Median of two strips/day used by those taking agents not considered to be risk for causing hypoglycemia

Prevalence of active migraine decreased linearly in the 24 years prior to diabetes diagnosis

Fewer than a third of normal-weight adults, 8 percent of overweight adults are metabolically healthy

As we move into 2019 we may find that our patients are eligible for more technology and less expensive medications. Over the past few days I have been receiving ads on my Facebook page for the Dexcom 5 and 6 and Medicare coverage. Since my wife has been using mealtime …